- Home
- ANGO vs CLLS Comparison
ANGO vs CLLS Comparison
Compare ANGO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGO | CLLS |
|---|---|---|
| Founded | 1988 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 394.4M |
| IPO Year | 2004 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANGO | CLLS |
|---|---|---|
| Price | $13.31 | $2.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $18.00 | $8.33 |
| AVG Volume (30 Days) | ★ 326.7K | 39.8K |
| Earning Date | 04-02-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $291,010,000.00 | N/A |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $4.96 | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $8.36 | $1.42 |
| 52 Week High | $13.99 | $5.48 |
Technical Indicators
Market Signals| Indicator | ANGO | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 66.58 | 35.65 |
| Support Level | $13.02 | $2.49 |
| Resistance Level | $13.37 | $3.83 |
| Average True Range (ATR) | 0.44 | 0.16 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 77.63 | 19.72 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.